Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 4Phase 1 2

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Breast 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 63Lymphoma, Large B-Cell, Diffuse 60Lymphoma 57Lymphoma, Non-Hodgkin 54Lymphoma, Follicular 43Lymphoma, Mantle-Cell 31Lymphoma, B-Cell, Marginal Zone 26Lymphoma, B-Cell 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Leukemia 19Burkitt Lymphoma 19Waldenstrom Macroglobulinemia 16Recurrence 16Hodgkin Disease 13Multiple Myeloma 9Lymphoma, Large-Cell, Immunoblastic 9Hematologic Neoplasms 8Leukemia, Myeloid, Acute 7Neoplasms, Plasma Cell 6Neoplasms 6Myelodysplastic Syndromes 6Leukemia, Prolymphocytic 6Lymphoma, T-Cell 5Intraocular Lymphoma 5Leukemia, Hairy Cell 4Neoplasm Metastasis 3Myeloproliferative Disorders 3Lymphoma, T-Cell, Peripheral 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, B-Cell 3

Interventions

romidepsin 12Cyclophosphamide 10fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Gemcitabine 7Bortezomib 7fludarabine 6Lenalidomide 6Filgrastim 6tanespimycin 5Vorinostat 5Magnetic Resonance Spectroscopy 5Etoposide 5Biopsy 5belinostat 4Tacrolimus 4Depsipeptides 4Brentuximab Vedotin 4Whole-Body Irradiation 3Specimen Handling 3Radiotherapy 3Oxaliplatin 3Nivolumab 3Methylprednisolone 3Lactones 3Irinotecan 3Ipilimumab 3Doxorubicin 3Dexamethasone 3Dasatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, T-Cell, Cutaneous × Rituximab × Clear all
NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Mayo Clinic

Phase 1 Terminated
17 enrolled
BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT02663518 2024-05-10

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Pfizer

Phase 1 Terminated
249 enrolled 43 charts
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Hodgkin Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡